CY1118207T1 - Συμπλοκα χηλικων ενωσεων ολιγονουκλεοτιδιων - Google Patents
Συμπλοκα χηλικων ενωσεων ολιγονουκλεοτιδιωνInfo
- Publication number
- CY1118207T1 CY1118207T1 CY20161101037T CY161101037T CY1118207T1 CY 1118207 T1 CY1118207 T1 CY 1118207T1 CY 20161101037 T CY20161101037 T CY 20161101037T CY 161101037 T CY161101037 T CY 161101037T CY 1118207 T1 CY1118207 T1 CY 1118207T1
- Authority
- CY
- Cyprus
- Prior art keywords
- chelating
- oligonucleotide
- divalent
- complexes
- oligonucleotics
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 8
- 150000001768 cations Chemical class 0.000 abstract 2
- 239000013522 chelant Substances 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 229910052751 metal Inorganic materials 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37525710P | 2010-08-20 | 2010-08-20 | |
| PCT/CA2011/000956 WO2012021985A1 (en) | 2010-08-20 | 2011-08-18 | Oligonucleotide chelate complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118207T1 true CY1118207T1 (el) | 2017-06-28 |
Family
ID=45594559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101037T CY1118207T1 (el) | 2010-08-20 | 2016-10-17 | Συμπλοκα χηλικων ενωσεων ολιγονουκλεοτιδιων |
Country Status (35)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2049664T3 (da) | 2006-08-11 | 2012-01-02 | Prosensa Technologies Bv | Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser |
| HRP20150759T1 (hr) | 2007-05-11 | 2015-08-14 | Adynxx, Inc. | Ekspresija gena i bolovi |
| ES2564563T3 (es) | 2007-10-26 | 2016-03-23 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar trastornos del músculo |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CN118581086A (zh) | 2012-01-27 | 2024-09-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| EP4400169A3 (en) | 2012-04-23 | 2024-12-25 | Vico Therapeutics B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
| PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| TWI635864B (zh) * | 2012-05-18 | 2018-09-21 | 雷普利可公司 | 寡核苷酸螯合複合物－多肽組合物及方法 |
| CN110257379B (zh) | 2012-07-03 | 2023-08-11 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
| CN104837501B (zh) * | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| HRP20231400T1 (hr) | 2014-07-10 | 2024-02-16 | Replicor Inc. | Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d |
| BR112017002629A2 (pt) | 2014-08-15 | 2018-02-20 | Adynxx, Inc. | decoys de oligonucleotídeo para o tratamento de dor |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| SMT202000389T1 (it) * | 2015-04-23 | 2020-09-10 | Geron Corp | Metodi di preparazione di polinucleotidi usando composizioni di sali cationici multivalenti |
| CN113286803A (zh) * | 2018-11-08 | 2021-08-20 | 阿里戈斯治疗公司 | S-抗原转运抑制寡核苷酸聚合物和方法 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021198958A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| AU2021383758A1 (en) * | 2020-11-20 | 2023-06-15 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| US20240336921A1 (en) | 2021-07-09 | 2024-10-10 | Glaxo Smith Kline Intellectual Property (No. 3) Limited | Use of oligonucleotides for individuals with renal impairment |
| WO2024255846A1 (en) * | 2023-06-16 | 2024-12-19 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1019429A4 (en) * | 1997-08-20 | 2001-08-08 | Somagenics Inc | ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE |
| JP3667047B2 (ja) * | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| US20070105116A1 (en) * | 2003-09-02 | 2007-05-10 | Japan Science And Technology Agency | Metal complex type nucleic acid |
| WO2005026188A1 (ja) * | 2003-09-08 | 2005-03-24 | Japan Science And Technology Agency | 金属錯体型核酸 |
| JP2009500020A (ja) * | 2005-07-01 | 2009-01-08 | バイオヴェリス コーポレイション | 核酸を検出、増幅および／また単離するための組成物および方法 |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
-
2011
- 2011-08-18 PH PH1/2013/500192A patent/PH12013500192B1/en unknown
- 2011-08-18 NZ NZ606364A patent/NZ606364A/en unknown
- 2011-08-18 SI SI201130985A patent/SI2605794T1/sl unknown
- 2011-08-18 CA CA2806616A patent/CA2806616C/en active Active
- 2011-08-18 AU AU2011291401A patent/AU2011291401B2/en active Active
- 2011-08-18 EA EA201300259A patent/EA026660B1/ru unknown
- 2011-08-18 HR HRP20161333TT patent/HRP20161333T1/hr unknown
- 2011-08-18 JP JP2013524318A patent/JP5775581B2/ja active Active
- 2011-08-18 US US13/212,306 patent/US8513211B2/en active Active
- 2011-08-18 KR KR1020137007008A patent/KR101606495B1/ko not_active Expired - Fee Related
- 2011-08-18 CA CA2855690A patent/CA2855690C/en active Active
- 2011-08-18 RS RS20160869A patent/RS55245B1/sr unknown
- 2011-08-18 MX MX2013001668A patent/MX340294B/es active IP Right Grant
- 2011-08-18 DK DK11817618.9T patent/DK2605794T3/en active
- 2011-08-18 KR KR1020157017340A patent/KR20150082685A/ko not_active Withdrawn
- 2011-08-18 PT PT118176189T patent/PT2605794T/pt unknown
- 2011-08-18 BR BR112013003875-6A patent/BR112013003875B1/pt not_active IP Right Cessation
- 2011-08-18 LT LTEP11817618.9T patent/LT2605794T/lt unknown
- 2011-08-18 HU HUE11817618A patent/HUE029521T2/en unknown
- 2011-08-18 KR KR20157007582A patent/KR20150039873A/ko not_active Withdrawn
- 2011-08-18 PL PL11817618T patent/PL2605794T3/pl unknown
- 2011-08-18 EP EP11817618.9A patent/EP2605794B1/en active Active
- 2011-08-18 CN CN201180035946.6A patent/CN103052405B/zh active Active
- 2011-08-18 WO PCT/CA2011/000956 patent/WO2012021985A1/en not_active Ceased
- 2011-08-18 MY MYPI2013000544A patent/MY160961A/en unknown
- 2011-08-18 SG SG2013004957A patent/SG187165A1/en unknown
- 2011-08-18 ES ES11817618.9T patent/ES2598556T3/es active Active
- 2011-08-18 CN CN201410046103.1A patent/CN103768086B/zh active Active
-
2013
- 2013-01-15 IL IL224237A patent/IL224237A/en active IP Right Grant
- 2013-01-18 ZA ZA2013/00497A patent/ZA201300497B/en unknown
- 2013-02-11 CO CO13027675A patent/CO6670525A2/es unknown
- 2013-02-13 CL CL2013000445A patent/CL2013000445A1/es unknown
- 2013-02-14 GT GT201300040A patent/GT201300040A/es unknown
- 2013-02-14 DO DO2013000041A patent/DOP2013000041A/es unknown
- 2013-02-19 CR CR20130069A patent/CR20130069A/es unknown
- 2013-02-19 EC ECSP13012449 patent/ECSP13012449A/es unknown
- 2013-02-20 CU CU2013000022A patent/CU20130022A7/es unknown
- 2013-05-30 US US13/905,318 patent/US8716259B2/en active Active
-
2016
- 2016-10-13 SM SM201600370T patent/SMT201600370B/it unknown
- 2016-10-17 CY CY20161101037T patent/CY1118207T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118207T1 (el) | Συμπλοκα χηλικων ενωσεων ολιγονουκλεοτιδιων | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| CY1122337T1 (el) | Παραγωγα σουλφamοϋλθεiοφaiνamiδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| PH12018501812A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| CY1124345T1 (el) | Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| BR112014013526A2 (pt) | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados | |
| NZ610851A (en) | Compounds and compositions for the treatment of cancer | |
| NZ630465A (en) | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia | |
| CO6592104A2 (es) | Compuesto heterociclico | |
| EA201591457A8 (ru) | Терапевтические соединения | |
| NZ599045A (en) | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| WO2014194030A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| PH12015501088A1 (en) | Dimeric compounds | |
| NZ631082A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| PH12013502334A1 (en) | Method for treatment of advanced solid tumors | |
| CY1117541T1 (el) | Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8) | |
| CL2016002490A1 (es) | Métodos para preparar productos compuestos de lignocelulosa con aglutinantes oxidativos y catalizadores metálicos acomplejados | |
| EP4520745A3 (en) | Double targeted constructs to affect tumor kill | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. |